Q-omics provides the consensus-scored PABPN1L profile across patient tissues and cancer cell-line models. PABPN1L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PABPN1L is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, PABPN1L RNA expression shows 9,283 significant gene co-expression associations, with the highest sampling consensus in UCS. Together, these results highlight KIRC, LUSC, and UCS as cancer lineages where PABPN1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PABPN1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PABPN1L survival associations across molecular data types. PABPN1L RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PABPN1L RNA expression–survival associations across cancer types. High PABPN1L expression shows unfavorable associations in KIRC and THCA, but favorable associations in PAAD, LUAD, HNSC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for PABPN1L RNA expression.
This table summarizes PABPN1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for PABPN1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PABPN1L shows lower tumor expression in LUSC, UCEC and LUAD and higher tumor expression in KIRC. The LUSC box plot shows higher PABPN1L RNA expression in normal versus tumor tissue (log2 FC = −0.056, t-test p = .015).
This table shows molecular features associated with PABPN1L in patient tissues and cancer cell lines. In patient samples, PABPN1L shows the broadest associations at the RNA and protein expression levels, with UCS recurring as the lineage with the largest associated feature set. In cancer cell lines, PABPN1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
